Absci Corporation is a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design. Absci Corporation is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | $4.53M |
| Net Income (Most Recent Fiscal Year) | $-103.11M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 73.91 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.79 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2231.01% |
| Net Margin (Trailing 12 Months) | -2232.13% |
| Return on Equity (Trailing 12 Months) | -53.69% |
| Return on Assets (Trailing 12 Months) | -45.89% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.72 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.72 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.56 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.21 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.94 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.92 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 127.56M |
| Free Float | 114.18M |
| Market Capitalization | $355.89M |
| Average Volume (Last 20 Days) | 2.69M |
| Beta (Past 60 Months) | 2.06 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.49% |
| Percentage Held By Institutions (Latest 13F Reports) | 52.05% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |